In our June Research Report, OneMedResearch explores the potential impact of the JOBS Act on the life sciences sector. This month we have also initiated coverage on Opexa Therapeutics and OncoSec Medical, […]
Zymeworks Invited to Present AntiBody Technology at OneMedForum NY 2012
Zymeworks Inc. is a privately held biotechnology company committed to developing best-in-class protein therapeutics for the treatment of cancer.
Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study
According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer.
OncoSec to Present at Upcoming Investor and Scientific Conferences
OncoSec Medical is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease.
Industry Veteran Named CEO of Vigilant Biosciences
New “rinse and spit” screen for oral cancer could reduce disfigurement and save lives. Vigilant Biosciences, Inc., recently announced the appointment of David Barshis as Chief Executive Officer.
Immunotherapy Trains the Immune System to Attack Cancer Cells
Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness.
Editor’s Note June 5, 2012
This week, we respond to a recent Wall Street Journal article documenting immunotherapy as a new treatment for Cancer. We tell you what companies they missed. OneMedRadio brings you management interviews with […]
Four Cancer Therapies to Watch
On June 1, more than 25,000 cancer specialists will come together at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. With ASCO hours away, we look at some small biotech companies making headway in cancer treatment.
